IL27 and asthma: Yoshimoto and his team [7] reported that IL-27 suppressed Th2 cell development and Th2 cytokine production from polarized Th2 cells and that IL-27 could significantly improve the pathologic symptoms through large-dose i.n. administration during the OVA-challenge stage in an OVA-induced mouse asthma model.